title: Suppression of morphine withdrawal syndrome by interleukin-2 and its gene.
abstract: The naloxone-precipitated withdrawal syndrome in mice and rats after intrathecal injection of recombinant human interleukin-2 protein (rIL-2) or its gene was studied. The results showed that rIL-2 could significantly decrease the number of jumps in mice. In rats, rIL-2 significantly suppressed irritating, diarrhea, weight loss, abnormal posture and salivation. Tendencies towards reductions in teeth chewing and dog-shaking were also observed. Furthermore, pcDNA3-IL-2 (8 microg DNA) had a similar effect as 1x10 IU rIL-2 protein on inhibition of morphine withdrawal syndrome in mice, and the expression of rIL-2 protein in spinal cord could be detected for 6 days. These findings provided further evidence for the neuroregulatory function of an immunological molecule such as IL-2.
authors.affiliation: Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, P.R. China.
authors.forename: Jinfa
authors.initials: J
authors.lastname: Gu
authors.forename: Mingzhong
authors.initials: M
authors.lastname: Yao
authors.forename: Jinhui
authors.initials: J
authors.lastname: Wang
authors.forename: Wenhua
authors.initials: W
authors.lastname: Zhou
authors.forename: Guodong
authors.initials: G
authors.lastname: Yang
authors.forename: Huifeng
authors.initials: H
authors.lastname: Liu
authors.forename: Zilai
authors.initials: Z
authors.lastname: Zhang
authors.forename: Xinyuan
authors.initials: X
authors.lastname: Liu
mesh_terms: D000818:Animals; D003587:Cytomegalovirus / Q000235:genetics; D018076:DNA, Complementary / Q000008:administration & dosage; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D007278:Injections, Spinal; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics*; D008297:Male; D051379:Mice; D009021:Morphine Dependence / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*; D009270:Naloxone / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics; D013375:Substance Withdrawal Syndrome / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*
chemical_list: D018076:DNA, Complementary; D007376:Interleukin-2; D011994:Recombinant Proteins; D009270:Naloxone